Pfizer Inc. on Tuesday unveiled a new online platform designed to help simplify and coordinate healthcare for consumers, adding momentum to an emerging trend in big pharma that has drawn criticism from some provider groups and policy experts.
One of Pfizer's vaccine programs failed to demonstrate its utility. Its competitors had the same issue with their programs.
On Thursday, the FDA cleared new versions of Pfizer's (PFE) and Moderna's (MRNA) COVID-19 vaccines that are designed to match COVID-19 strains currently circulating in the country.
It is never too early to start your investment journey.
US regulators have approved a new series of updated and improved COVID-19 vaccines to target a resurgence of the virus as new strains emerge. Pfizer Inc (NYSE:PFE, ETR:PFE) and Moderna Inc (NASDAQ:MRNA, ETR:0QF) are set to begin shipping immediately while a third US manufacturer, Novavax, expects to start deliveries later.
The Food and Drug Administration on Thursday gave Pfizer Inc. and Moderna Inc. approval for updated COVID-19 vaccines, as a summer wave of the virus is still rolling across the country.
The Food and Drug Administration approved updated Covid vaccines from Pfizer and Moderna, putting the shots on track to reach most Americans in the coming days as the virus surges. The jabs target a strain called KP.2, a descendant of the highly contagious omicron subvariant JN.1 that began circulating widely in the U.S. earlier this year.
24/7 Wall St. Insights Pfizer is one of the highest-yielding S&P 500 stocks.
Is Pfizer stock a buy or a sell as sales of its Covid products continue diving? Is PFE stock a buy or a sell right now?
After Pfizer's (PFE) better-than-expected second-quarter results and the bullish outlook for the year, investors who own Pfizer's stock may consider staying invested.
Social Security faces potential benefit reductions after 2035. Dividend-paying stocks can form a solid basis for a passive income portfolio.
Pfizer's (PFE) COVID and flu combination vaccine demonstrates a continued trend of higher responses against influenza A but fails to show non-inferiority against the influenza B strain.